NICE Clears Alimera’s Iluvien For DME In Patients With Artificial Lens
This article was originally published in The Pink Sheet Daily
Executive Summary
Alimera Sciences’s Iluvien gets reimbursement clearance in the U.K. for diabetic macular edema patients unresponsive to other therapies with the help of a price discount and the lack of cataract side effects by limiting its use to patients with artificial lens.
You may also be interested in...
Price Discount Paves The Way For NICE To Clear GSK’s Revolade
U.K. drug cost watchdog NICE has cleared Glaxo’s Revolade and Alcon's Jetrea but rejected Lilly's Alimta as maintenance therapy in a subgroup of lung cancer patients.
Alimera Resubmits Iluvien In U.S. As It Begins EU Launch
The Atlanta-based ophthalmology company hopes to succeed in third try with FDA, but must split its focus with Europe as it tries to roll out launches in several countries at once.
Lucentis Price Concessions Win Partial Victory; NICE Clears Drug With Restrictions
Britain's cost watchdog NICE changed its mind on Lucentis, and now recommends it for treating diabetic macular edema, after Novartis offered a steeper discount – but the eye drug’s price tag remains high, so only a subgroup of British patients will receive it.